JP2008500281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500281A5 JP2008500281A5 JP2007501804A JP2007501804A JP2008500281A5 JP 2008500281 A5 JP2008500281 A5 JP 2008500281A5 JP 2007501804 A JP2007501804 A JP 2007501804A JP 2007501804 A JP2007501804 A JP 2007501804A JP 2008500281 A5 JP2008500281 A5 JP 2008500281A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- peptide
- hse
- calcitonin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 229910052731 fluorine Inorganic materials 0.000 claims 18
- 229910052720 vanadium Inorganic materials 0.000 claims 16
- 229910052740 iodine Inorganic materials 0.000 claims 15
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 14
- 229910052700 potassium Inorganic materials 0.000 claims 13
- 229910052727 yttrium Inorganic materials 0.000 claims 12
- 102000055006 Calcitonin Human genes 0.000 claims 10
- 108060001064 Calcitonin Proteins 0.000 claims 10
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 10
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 10
- 229960004015 calcitonin Drugs 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 229910052698 phosphorus Inorganic materials 0.000 claims 10
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 7
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 6
- 208000008279 Dumping Syndrome Diseases 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000030814 Eating disease Diseases 0.000 claims 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 206010020772 Hypertension Diseases 0.000 claims 4
- 206010022489 Insulin Resistance Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 208000032395 Post gastric surgery syndrome Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000001352 cholecystitis Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 235000014632 disordered eating Nutrition 0.000 claims 4
- 208000004104 gestational diabetes Diseases 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 201000001421 hyperglycemia Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000001212 derivatisation Methods 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 2
- 229960002591 hydroxyproline Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108010068072 salmon calcitonin Proteins 0.000 claims 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 150000001336 alkenes Chemical class 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54327504P | 2004-02-11 | 2004-02-11 | |
| US55044704P | 2004-03-04 | 2004-03-04 | |
| PCT/US2005/004631 WO2006083254A1 (en) | 2004-02-11 | 2005-02-11 | Amylin family peptides and methods for making and using them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500281A JP2008500281A (ja) | 2008-01-10 |
| JP2008500281A5 true JP2008500281A5 (enExample) | 2008-03-13 |
Family
ID=34963236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501804A Pending JP2008500281A (ja) | 2004-02-11 | 2005-02-11 | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8114958B2 (enExample) |
| EP (2) | EP1716172B1 (enExample) |
| JP (1) | JP2008500281A (enExample) |
| KR (1) | KR101196122B1 (enExample) |
| AT (1) | ATE471340T1 (enExample) |
| AU (2) | AU2005320351B2 (enExample) |
| BR (1) | BRPI0507623A (enExample) |
| CA (1) | CA2556226A1 (enExample) |
| DE (1) | DE602005021858D1 (enExample) |
| ES (1) | ES2345113T3 (enExample) |
| IL (2) | IL177230A0 (enExample) |
| NZ (2) | NZ549332A (enExample) |
| RU (1) | RU2385878C2 (enExample) |
| WO (1) | WO2006083254A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005021858D1 (de) * | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US7671023B2 (en) | 2005-03-31 | 2010-03-02 | Amylin Pharmaceuticals, Inc. | Amylin agonist for treating depression, anxiety disorder and schizophrenia |
| WO2008097536A2 (en) | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
| CN102076353A (zh) * | 2008-06-25 | 2011-05-25 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽 |
| WO2010014225A2 (en) | 2008-07-30 | 2010-02-04 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
| CN102292346B (zh) | 2009-01-22 | 2015-12-02 | 关键生物科学有限公司 | 肥胖的治疗 |
| KR101673042B1 (ko) * | 2009-03-12 | 2016-11-04 | 키바이오사이언스 아게 | 당뇨병 및 대사 증후군의 치료 |
| US8748375B2 (en) | 2009-03-17 | 2014-06-10 | Amylin Pharmaceuticals, Llc | Methods for affecting body composition using amylin agonists |
| JP2012523434A (ja) | 2009-04-10 | 2012-10-04 | アミリン・ファーマシューティカルズ，インコーポレイテッド | エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物 |
| KR20120116942A (ko) | 2009-11-23 | 2012-10-23 | 아밀린 파마슈티칼스, 인크. | 폴리펩티드 접합체 |
| GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP3025728B1 (en) * | 2010-02-04 | 2018-08-08 | BioMarin Pharmaceutical Inc. | Method for purifying prokaryotic phenylalanine ammonia-lyase variants |
| EA201390450A1 (ru) | 2010-09-28 | 2013-07-30 | Амилин Фармасьютикалс, Ллк. | Полипептиды с увеличенной продолжительностью действия |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| RU2664859C2 (ru) | 2011-04-07 | 2018-08-23 | Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити | Аналоги длительно действующих пептидов |
| MX2013013802A (es) * | 2011-05-25 | 2014-04-25 | Amylin Pharmaceuticals Llc | Peptidos de amilina y derivados y usos de los mismos. |
| US20140221282A1 (en) | 2011-05-25 | 2014-08-07 | Astrazeneca Pharmaceuticals Lp | Long duration dual hormone conjugates |
| WO2012160212A1 (en) | 2011-05-25 | 2012-11-29 | Camurus Ab | Peptide controlled-release formulations |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| ES2732475T3 (es) | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
| WO2013059336A1 (en) * | 2011-10-18 | 2013-04-25 | Amylin Pharmaceuticals, Llc | Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties |
| MX351092B (es) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
| US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| EP2807187B1 (en) * | 2012-01-26 | 2017-07-26 | Christopher J. Soares | Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use |
| AU2013243920A1 (en) | 2012-04-03 | 2014-10-09 | Trustees Of Boston University | Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders |
| ES2640285T3 (es) | 2012-04-19 | 2017-11-02 | Novo Nordisk A/S | Análogos de amilina humana |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| JP2016506401A (ja) | 2012-12-21 | 2016-03-03 | サノフイ | 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体 |
| BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
| EP3027644B1 (en) * | 2013-07-30 | 2019-08-21 | Christopher J. Soares | Cgrp agonist peptides |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EA035791B1 (ru) | 2015-03-18 | 2020-08-11 | Зилэнд Фарма А/С | Аналоги амилина |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| BR102015031283A2 (pt) * | 2015-12-14 | 2018-09-18 | Univ Rio De Janeiro | Bioconjugado de amilina humana ou de análogos de amilinanão agregantes, composição, métodos para a preparação deuma composição, para o tratamento de uma doença oucondição e para estabilizar um composto amilino-mimético, e,medicamento |
| US11034745B2 (en) | 2016-01-04 | 2021-06-15 | Adepthera Llc | Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones |
| CN109475604B (zh) | 2016-02-09 | 2023-04-04 | 艾得佩索拉公司 | 长效型clr/ramp激动剂的配量和用途 |
| EP3506925B1 (en) | 2016-09-02 | 2023-09-06 | Christopher J. Soares | Use of cgrp receptor antagonists in treating glaucoma |
| AR109514A1 (es) | 2016-09-09 | 2018-12-19 | Zealand Pharma As | Análogos de amilina |
| EP3645031A4 (en) | 2017-06-30 | 2021-03-31 | Adepthera LLC | PEPTIDIC ANALOGUES |
| HUE066356T2 (hu) | 2017-08-24 | 2024-07-28 | Novo Nordisk As | GLP-1 készítmények és alkalmazásaik |
| KR20220070246A (ko) | 2019-09-23 | 2022-05-30 | 디디에스 리서치 인크. | 침투 증진제를 갖는 지질 소포 조성물 |
| PE20221575A1 (es) | 2020-02-18 | 2022-10-06 | Novo Nordisk As | Formulaciones farmaceuticas |
| MX2023011157A (es) | 2021-03-24 | 2024-01-25 | Glo Pharma Inc | Peptidos y metodos para reducir la pigmentacion de la piel. |
| MX2024005969A (es) | 2022-05-30 | 2024-06-11 | Zealand Pharma As | Formulaciones liquidas de analogos de amilina. |
| WO2024189611A1 (en) * | 2023-03-13 | 2024-09-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Stabilized analogues of calcitonin |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| GB8720115D0 (en) | 1987-08-26 | 1987-09-30 | Cooper G J S | Treatment of diabetes mellitus |
| FI900178A0 (fi) | 1988-05-13 | 1990-01-12 | Amgen Inc | Kompositioner och foerfarande foer behandling eller foerhindrande av infektioner hos djur. |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| US5580953A (en) | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| JPH06256210A (ja) | 1993-03-10 | 1994-09-13 | Hoechst Japan Ltd | 骨関連転写制御因子様タンパク質およびその製造法 |
| JPH07509008A (ja) | 1993-05-12 | 1995-10-05 | ユニバーシティ・オブ・シンシナティ | アミリン・アンタゴニストおよびアゴニスト |
| BR9407424A (pt) | 1993-09-07 | 1996-04-09 | Amylin Pharmaceuticals Inc | Métodos para regular motilidade gastrointestinal |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6143718A (en) | 1995-06-07 | 2000-11-07 | Amylin Pharmaceuticals, Inc. | Treatment of Type II diabetes mellutis with amylin agonists |
| US5686511A (en) | 1996-06-28 | 1997-11-11 | The Valspar Corporation | Esterifying epoxy resin with carboxyl polymer and quenching |
| US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| PT1629849E (pt) | 1997-01-07 | 2013-07-09 | Amylin Pharmaceuticals Llc | Composições farmacêuticas que compreendem exendinas e seus agonistas |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| DK1019077T4 (da) | 1997-08-08 | 2011-03-07 | Amylin Pharmaceuticals Inc | Hidtil ukendte exendinagonistforbindelser |
| US7220721B1 (en) | 1997-11-14 | 2007-05-22 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptides |
| JP2003522721A (ja) | 1997-11-14 | 2003-07-29 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規なエキセンジンアゴニスト化合物 |
| JP2001523688A (ja) | 1997-11-14 | 2001-11-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 新規エキセンジン・アゴニスト化合物 |
| US6936584B1 (en) | 1998-02-13 | 2005-08-30 | Amylin Pharmaceuticals, Inc. | Mixed amylin activity compounds |
| EP1053001B1 (en) * | 1998-02-13 | 2010-12-15 | Amylin Pharmaceuticals, Inc. | Novel mixed amylin activity compounds |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| RU2166258C2 (ru) * | 1999-07-01 | 2001-05-10 | Общество с ограниченной ответственностью Научно-производственный центр "Витиус" | Композиция фиточая |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US20030026182A1 (en) | 2001-08-06 | 2003-02-06 | Fischer Michael C. | Method and system for write clock synchronization in a data storage system |
| ES2425221T3 (es) * | 2003-05-30 | 2013-10-14 | Amylin Pharmaceuticals, Llc | Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas |
| US20060094652A1 (en) | 2004-02-11 | 2006-05-04 | Levy Odile E | Hybrid polypeptides with selectable properties |
| DE602005021858D1 (de) * | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| JP5638177B2 (ja) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| EP3000826A1 (en) | 2004-12-13 | 2016-03-30 | Amylin Pharmaceuticals, LLC | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| US7671023B2 (en) * | 2005-03-31 | 2010-03-02 | Amylin Pharmaceuticals, Inc. | Amylin agonist for treating depression, anxiety disorder and schizophrenia |
-
2005
- 2005-02-11 DE DE602005021858T patent/DE602005021858D1/de not_active Expired - Lifetime
- 2005-02-11 EP EP05723040A patent/EP1716172B1/en not_active Expired - Lifetime
- 2005-02-11 CA CA002556226A patent/CA2556226A1/en not_active Abandoned
- 2005-02-11 EP EP10006105A patent/EP2233497A3/en not_active Withdrawn
- 2005-02-11 AT AT05723040T patent/ATE471340T1/de not_active IP Right Cessation
- 2005-02-11 ES ES05723040T patent/ES2345113T3/es not_active Expired - Lifetime
- 2005-02-11 NZ NZ549332A patent/NZ549332A/en not_active IP Right Cessation
- 2005-02-11 AU AU2005320351A patent/AU2005320351B2/en not_active Ceased
- 2005-02-11 BR BRPI0507623-4A patent/BRPI0507623A/pt not_active IP Right Cessation
- 2005-02-11 RU RU2006132293/13A patent/RU2385878C2/ru not_active IP Right Cessation
- 2005-02-11 WO PCT/US2005/004631 patent/WO2006083254A1/en not_active Ceased
- 2005-02-11 US US10/589,054 patent/US8114958B2/en not_active Expired - Fee Related
- 2005-02-11 NZ NZ571824A patent/NZ571824A/en not_active IP Right Cessation
- 2005-02-11 JP JP2007501804A patent/JP2008500281A/ja active Pending
-
2006
- 2006-08-02 IL IL177230A patent/IL177230A0/en unknown
- 2006-09-08 KR KR1020067018379A patent/KR101196122B1/ko not_active Expired - Fee Related
-
2009
- 2009-12-17 IL IL202795A patent/IL202795A0/en unknown
-
2010
- 2010-08-20 AU AU2010212468A patent/AU2010212468A1/en not_active Ceased
-
2012
- 2012-02-01 US US13/364,250 patent/US8598120B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006132293A (ru) | Пептиды семейства амилинов и способы их получения и применения | |
| CA2320371A1 (en) | Inotropic and diuretic effects of exendin and glp-1 | |
| JP2023554046A5 (enExample) | ||
| AR038102A1 (es) | Analogos extendidos de peptido 1 de tipo glucagon | |
| CA2309356A1 (en) | Novel exendin agonist compounds | |
| JP2005534647A5 (enExample) | ||
| JP2023553591A5 (enExample) | ||
| EP2422808A3 (en) | Novel compounds and their effects on feeding behaviour | |
| JP2009529553A5 (enExample) | ||
| CA2412004A1 (en) | Glucagon-like peptide-1 analogs | |
| JP7554928B2 (ja) | Ｇｌｐ－１およびアミリン受容体の共作動薬 | |
| JP2019504057A5 (enExample) | ||
| CA2277112C (en) | Use of exendins and agonists thereof for the reduction of food intake | |
| PE20240890A1 (es) | Moduladores de los receptores acoplados a proteinas g | |
| CA2682499A1 (en) | Composition and microsphere for controlled-release of exendin, and method of preparing the same | |
| HRP20100062T1 (hr) | Glp-1 (glukagon-like peptid-1) fuzijski polipeptidi sa povećanom otpornošću na peptidaze | |
| UA102370C2 (ru) | Пептид, фармацевтическая композиция и лекарственное средство, которое его содержит, способ лечения и/или предупреждения диабета и сопутствующих ожирению заболеваний, способ снижения аппетита, снижение поглощения пищи и снижение массы тела | |
| GB2640988A (en) | Amylin analogues | |
| ATE332921T1 (de) | Neue peptidzusammensetzungen und deren verwendung,insbesondere zur herstellung von pharmazeutischen zusammensetzungen mit wirkung gegen das hepatitis-c-virus | |
| RU2025117213A (ru) | Аналоги амилина | |
| US20250074964A1 (en) | Stable glp-1 analogs for the treatment of human disease and disorders | |
| GB2642930A (en) | Compounds | |
| RU2025125845A (ru) | Соединения | |
| ES2550536T3 (es) | Motivos de la familia de polipéptidos pancreáticos, polipéptidos y métodos que los comprenden | |
| JP2025502749A5 (enExample) |